SFDA Approves Leqembi As The First Alzheimer’s Treatment For Patients In Saudi Arabia

The Saudi Food and Drug Authority (SFDA) has approved Leqembi (lecanemab) for treating mild cognitive impairment or mild dementia due to Alzheimer's disease. This approval is significant as it is the first Alzheimer's treatment sanctioned in Saudi Arabia. The drug is designed for patients with no copies or only one copy of the apolipoprotein E4 (ApoE4) gene variant.

Lecanemab represents a novel biologic therapy, employing monoclonal antibody technology. Unlike previous treatments, it aims to slow Alzheimer's progression rather than just ease symptoms. It targets beta-amyloid proteins in the brain, reducing plaque formation linked to cognitive decline. Administered bi-weekly through intravenous infusion, this therapy offers a new approach to managing Alzheimer's.

The SFDA's decision followed a comprehensive evaluation of lecanemab's efficacy, safety, and quality. Clinical trials indicated that the drug effectively slowed disease progression compared to a placebo. These trials used established clinical measures to assess its effectiveness in treating Alzheimer's disease.

Monitoring and Safety Measures

Common side effects observed included headaches, infusion-related reactions, and amyloid-related imaging abnormalities (ARIA). ARIA refers to abnormal changes in brain MRI scans associated with treatment, such as cerebral edema or microhemorrhages. Regular patient monitoring during treatment is crucial for tracking these side effects.

Genetic Considerations and Risk Management

The SFDA highlighted the importance of evaluating patients' genetic profiles, specifically their ApoE4 status, before starting therapy. This assessment helps minimize adverse effects. Additionally, the company must monitor post-marketing data and provide periodic reports on the drug's efficacy and safety.

A risk management plan is required to ensure safe and optimal use of lecanemab. This initiative aligns with SFDA's commitment to improving access to high-quality treatments in Saudi Arabia, particularly those developed through advanced biotechnological methods.

With inputs from SPA